CPIX

Over the past six months, several key events have impacted Cumberland Pharmaceuticals' stock price. Cumberland Pharmaceuticals reported strong financial performance for the fourth quarter and full year 2025. The U.S. Food and Drug Administration (FDA) approved an expanded indication for Caldolor (ibuprofen) Injection to include the management of postoperative pain. Cumberland Pharmaceuticals announced a strategic transaction to sell its portfolio of FDA-approved brands in the U.S. to Apotex Inc. for $100 million in cash, subject to shareholder approval. The company reported Q1 2026 net revenues of $9.1 million, a 5% increase compared to Q1 2025 after excluding a $3 million milestone payment received in the prior year, and posted a net loss of approximately $3.3 million for the quarter, compared to a net income of $1.2 million in Q1 2025, following which CPIX shares declined by 19.9% the next day.